ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M

ADC Therapeutics SA

Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.
Cash and cash equivalents ~$278.5M at Q4-end; cash runway extended to Q4 2025 (prev. mid-2025).
LOTIS-7 combo trial cleared first dosing cohort with no DLT; first 5 evaluable patients all showed response.
ADCT-601 (AXL) reached MTD; early antitumor activity in monotherapy and combination; dose optimization ongoing.
Discontinued ADCT-901 (KAAG1) due to limited efficacy; reallocating capital to prioritized pipeline programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.